Salvage chemotherapy with CCNU and methotrexate for small cell lung cancer resistant to CAV/PE alternating chemotherapy

C. Gridelli; A. Contegiacomo; R. Lauria; M. Gentile; G. Airoma; S. De Placido; F. Perrone; G. Ferrante; A. R. Bianco

Salvage chemotherapy with CCNU and methotrexate for small cell lung cancer resistant to CAV/PE alternating chemotherapy

C. Gridelli, A. Contegiacomo, R. Lauria, M. Gentile, G. Airoma, S. De Placido, F. Perrone, G. Ferrante, A. R. Bianco

Istituto Nazionale Tumori Fondazione G. Pascale

Research output: Contribution to journal › Article › peer-review

Abstract

CCNU and methotrexate were employed as salvage treatment in 34 small cell lung cancer patients resistant to CAV/PE alternating induction chemotherapy. In the 33 evaluable patients we observed an objective response rate of 21.2% and 3% complete response; median survival was 4 months with 2 patients alive 18 months from starting salvage chemotherapy. The treatment was well tolerated. CCNU and methotrexate has shown to be a moderately active and tolerable salvage treatment for small cell lung cancer after CAV/PE alternating first-line chemotherapy.

Original language	English
Pages (from-to)	506-510
Number of pages	5
Journal	Tumori
Volume	77
Issue number	6
Publication status	Published - 1991

ASJC Scopus subject areas

Cancer Research

Access to Document

Fingerprint Dive into the research topics of 'Salvage chemotherapy with CCNU and methotrexate for small cell lung cancer resistant to CAV/PE alternating chemotherapy'. Together they form a unique fingerprint.

Cite this

@article{2d58d2aab25b49d4ab40192d91cefb09,

title = "Salvage chemotherapy with CCNU and methotrexate for small cell lung cancer resistant to CAV/PE alternating chemotherapy",

abstract = "CCNU and methotrexate were employed as salvage treatment in 34 small cell lung cancer patients resistant to CAV/PE alternating induction chemotherapy. In the 33 evaluable patients we observed an objective response rate of 21.2% and 3% complete response; median survival was 4 months with 2 patients alive 18 months from starting salvage chemotherapy. The treatment was well tolerated. CCNU and methotrexate has shown to be a moderately active and tolerable salvage treatment for small cell lung cancer after CAV/PE alternating first-line chemotherapy.",

author = "C. Gridelli and A. Contegiacomo and R. Lauria and M. Gentile and G. Airoma and {De Placido}, S. and F. Perrone and G. Ferrante and Bianco, {A. R.}",

year = "1991",

language = "English",

volume = "77",

pages = "506--510",

journal = "Tumori",

issn = "0300-8916",

publisher = "SAGE Publications Ltd",

number = "6",

}

TY - JOUR

T1 - Salvage chemotherapy with CCNU and methotrexate for small cell lung cancer resistant to CAV/PE alternating chemotherapy

AU - Gridelli, C.

AU - Contegiacomo, A.

AU - Lauria, R.

AU - Gentile, M.

AU - Airoma, G.

AU - De Placido, S.

AU - Perrone, F.

AU - Ferrante, G.

AU - Bianco, A. R.

PY - 1991

Y1 - 1991

N2 - CCNU and methotrexate were employed as salvage treatment in 34 small cell lung cancer patients resistant to CAV/PE alternating induction chemotherapy. In the 33 evaluable patients we observed an objective response rate of 21.2% and 3% complete response; median survival was 4 months with 2 patients alive 18 months from starting salvage chemotherapy. The treatment was well tolerated. CCNU and methotrexate has shown to be a moderately active and tolerable salvage treatment for small cell lung cancer after CAV/PE alternating first-line chemotherapy.

AB - CCNU and methotrexate were employed as salvage treatment in 34 small cell lung cancer patients resistant to CAV/PE alternating induction chemotherapy. In the 33 evaluable patients we observed an objective response rate of 21.2% and 3% complete response; median survival was 4 months with 2 patients alive 18 months from starting salvage chemotherapy. The treatment was well tolerated. CCNU and methotrexate has shown to be a moderately active and tolerable salvage treatment for small cell lung cancer after CAV/PE alternating first-line chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0026350064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026350064&partnerID=8YFLogxK

M3 - Article

C2 - 1666468

AN - SCOPUS:0026350064

VL - 77

SP - 506

EP - 510

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 6

ER -